Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

Blood (2024) 143 (16): 1616–1627.

https://doi.org/10.1182/blood.2023021959

Published: 2024

Includes: Supplemental data

Journal Articles

Long-Term Remissions after First-Line Autologous Stem Cell Transplantation for Mantle Cell Lymphoma

Colin Stewart, Carolyn Owen, Neil Chua, Anthea Peters, Mona Shafey, Douglas A. Stewart, Robert Puckrin

Blood (2023) 142 (Supplement 1): 3599.

https://doi.org/10.1182/blood-2023-178097

Published: 2023

Journal Articles

Response to Subsequent Novel Therapies and Time to Second Progression-Free Survival Event in the MURANO Trial in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with Fixed-Dose Venetoclax Plus Rituximab

Rosemary Anne Harrup, Arnon P. Kater, Barbara F. Eichhorst, Carolyn Owen, Brenda Chyla, Hyun Yong Jin, Yanwen Jiang, Yi Meng Chang, Rosemary Millen, Marcus Lefebure, Maria Thadani-Mulero, Michelle Boyer, John F. Seymour

Blood (2023) 142 (Supplement 1): 1898.

https://doi.org/10.1182/blood-2023-177567

Published: 2023

Journal Articles

A Real-World Evidence Study of the Temporal Evolution in Treatment Patterns and Outcomes for Chronic Lymphocytic Leukemia

Winson Y. Cheung, Devon J. Boyne, Tamer N. Jarada, Chantelle Carbonell, Carolyn Owen

Blood (2023) 142 (Supplement 1): 7380.

https://doi.org/10.1182/blood-2023-178879

Published: 2023

Journal Articles

Improving the Utilization and Tolerability of Thiotepa-Based Autologous Stem Cell Transplantation in Primary CNS Lymphoma

Robert Puckrin, Colin Stewart, Carolyn Owen, Lesley E. Street, Sarah Perry, Peter Duggan, Mona Shafey, Neil Chua, Douglas A. Stewart

Blood (2023) 142 (Supplement 1): 3595.

https://doi.org/10.1182/blood-2023-178085

Published: 2023

Journal Articles

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Blood (2023) 142 (Supplement 1): 634.

https://doi.org/10.1182/blood-2023-177713

Published: 2023

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN):Multi-Center Collaboration and Global Registry Program

Blood (2023) 142 (Supplement 1): 1543.

https://doi.org/10.1182/blood-2023-188546

Published: 2023

Journal Articles

Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1 , GATA2 and DDX41

Anna L. Brown, Claire Homan, Michael W. Drazer, Kai Yu, David Lawrence, Jinghua Feng, Luis Arriola-Martinez, Matthew Pozsgai, Kelsey McNeely, Thuong Ha, Parvathy Venugopal, Peer Arts, Sarah King-Smith, Jesse JC Cheah, Mark Armstrong, Csaba Bödör, Paul Wang, Alan B. Cantor, Mario Cazzola, Erin Degelman, Courtney D. DiNardo, Nicolas Duployez, Remi Favier, Stefan Fröhling, Ana Rio-Machin, Jeffery M. Klco, Alwin Krämer, Mineo Kurokawa, Joanne Lee, Luca Malcovati, Neil V Morgan, Georges Natsoulis, Carolyn Owen, Keyur P. Patel, Claude Preudhomme, Hana Raslova, Hugh Young Rienhoff, Jr., Tim Ripperger, Rachael Schulte, Kiran Tawana, Elvira Deolinda Rodrigues Pereira Velloso, Benedict Yan, Raman Sood, Amy Hsu, Steven M. Holland, Kerry Phillips, Nicola Poplawski, Milena Babic, Erika M Kwon Kim, Andrew H. Wei, Cecily Forsyth, Helen Mar Fan, Ian D Lewis, Julian Cooney, Rachel Susman, Lucy C Fox, Piers Blombery, Deepak Singhal, Devendra Hiwase, Andreas W Schreiber, Christopher N Hahn, Hamish S Scott, Paul P. Liu, Lucy A. Godley

Blood (2022) 140 (Supplement 1): 4030–4033.

https://doi.org/10.1182/blood-2022-167600

Published: 2022

Journal Articles

Initiating First-Line (1L) Ibrutinib (Ibr) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched Population of ≥65 Years

Paolo Ghia, Carolyn Owen, Jacqueline C. Barrientos, Paul M. Barr, Anthony R. Mato, Chunxue Shi, Anita Szoke, Chris Abbazio, Gabriel S. Krigsfeld, Jan A. Burger

Blood (2022) 140 (Supplement 1): 4159–4161.

https://doi.org/10.1182/blood-2022-163257

Published: 2022

Journal Articles

Quality of Life in Patients with Chronic Lymphocytic Leukemia Initiating Venetoclax in Routine Clinical Practice across Canada: Results from the Devote Study

Andrew Aw, Versha Banerji, Sarah-Jane Bull, Pierre-André Fournier, Anthea Peters, Carolyn Owen

Blood (2022) 140 (Supplement 1): 12425–12426.

https://doi.org/10.1182/blood-2022-156749

Published: 2022

Journal Articles

Long-Term Host Immune Changes Following Treatment with Venetoclax Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia

Arnon P. Kater, Barbara Eichhorst, Carolyn Owen, Ulrich Jaeger, Brenda Chyla, Marcus Lefebure, Rosemary Millen, Yanwen Jiang, Maria Thadani-Mulero, John F. Seymour

Blood (2022) 140 (Supplement 1): 7010–7012.

https://doi.org/10.1182/blood-2022-158275

Published: 2022

Journal Articles

Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study

Blood (2022) 140 (Supplement 1): 228–230.

https://doi.org/10.1182/blood-2022-156070

Published: 2022

Journal Articles

External Validation of the FLIPI Risk Score Measured at Initial Diagnosis and POD24 Among Previously Treated Individuals with Progressed Follicular Lymphoma in Alberta, Canada

Carolyn Owen, Neil Chua, Devon Boyne, Ofodile Joe-Uzuegbu, Huma Shakir, Priyanka Gonga, Darren Brenner, Julia Elia-Pacitti, Emmanuel Ewara, Winson Y Cheung

Blood (2022) 140 (Supplement 1): 8024–8025.

https://doi.org/10.1182/blood-2022-160340

Published: 2022

Journal Articles

Real-World Outcomes of Consolidative Autotransplant for High-Risk Large B-Cell Lymphoma

Robert Puckrin, Russell Sterrett, Neil Chua, Carolyn Owen, Peter Duggan, Mona Shafey, Douglas A. Stewart

Blood (2022) 140 (Supplement 1): 10581–10582.

https://doi.org/10.1182/blood-2022-162850

Published: 2022

Journal Articles

First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study

Blood (2021) 138 (Supplement 1): 70.

https://doi.org/10.1182/blood-2021-148666

Published: 2021

Journal Articles

Tumor Lysis Syndrome: Incidence, Mitigation and Management in Patients with Chronic Lymphocytic Leukemia Initiating Venetoclax in Routine Clinical Practice (DEVOTE) across Canada

Versha Banerji, Nizar Abdel-Samad, Andrew Aw, Sarah-Jane Bull, Pierre-André Fournier, Nathalie Johnson, Nicole B. Laferriere, Paola Lembo, Christina H Pelizon, Anthea Peters, Carolyn Owen

Blood (2021) 138 (Supplement 1): 3744.

https://doi.org/10.1182/blood-2021-146001

Published: 2021

Journal Articles

Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

Blood (2021) 138 (Supplement 1): 639.

https://doi.org/10.1182/blood-2021-153146

Published: 2021

Journal Articles

Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx)

John F. Seymour, Jenny Qun Wu, Relja Popovic, Barbara Eichhorst, Peter Hillmen, Thomas J. Kipps, Anton W. Langerak, Carolyn Owen, Julie Dubois, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Fengjiao Dunbar, Yanwen Jiang, Brenda Chyla, Michelle Boyer, Maria Thadani-Mulero, Marcus Lefebure, Rosemary Harrup, Arnon P. Kater

Blood (2021) 138 (Supplement 1): 1548.

https://doi.org/10.1182/blood-2021-147731

Published: 2021

Journal Articles

Retrospective Review of Treatment Patterns and Outcomes of DLBCL in the Very Elderly: A Single Centre Experience

Farheen Manji, MD, Carolyn Owen, MDFRCPC

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-139654

Published: 2020

Journal Articles

Generalizability of Landmark Clinical Trials in Diffuse Large B Cell Lymphoma to Real-World Patients: A Single-Centre Retrospective Cohort Study

Marta Davidson, MDPhDFRCPC, Alexandra Rice, MD, Douglas A. Stewart, MD FRCPC, Carolyn Owen, MDFRCPC

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-137541

Published: 2020

NARROW

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

Long-Term Remissions after First-Line Autologous Stem Cell Transplantation for Mantle Cell Lymphoma

Response to Subsequent Novel Therapies and Time to Second Progression-Free Survival Event in the MURANO Trial in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with Fixed-Dose Venetoclax Plus Rituximab

A Real-World Evidence Study of the Temporal Evolution in Treatment Patterns and Outcomes for Chronic Lymphocytic Leukemia

Improving the Utilization and Tolerability of Thiotepa-Based Autologous Stem Cell Transplantation in Primary CNS Lymphoma

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN):Multi-Center Collaboration and Global Registry Program

Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1 , GATA2 and DDX41

Initiating First-Line (1L) Ibrutinib (Ibr) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched Population of ≥65 Years

Quality of Life in Patients with Chronic Lymphocytic Leukemia Initiating Venetoclax in Routine Clinical Practice across Canada: Results from the Devote Study

Long-Term Host Immune Changes Following Treatment with Venetoclax Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia

Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study

External Validation of the FLIPI Risk Score Measured at Initial Diagnosis and POD24 Among Previously Treated Individuals with Progressed Follicular Lymphoma in Alberta, Canada

Real-World Outcomes of Consolidative Autotransplant for High-Risk Large B-Cell Lymphoma

First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study

Tumor Lysis Syndrome: Incidence, Mitigation and Management in Patients with Chronic Lymphocytic Leukemia Initiating Venetoclax in Routine Clinical Practice (DEVOTE) across Canada

Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx)

Retrospective Review of Treatment Patterns and Outcomes of DLBCL in the Very Elderly: A Single Centre Experience

Generalizability of Landmark Clinical Trials in Diffuse Large B Cell Lymphoma to Real-World Patients: A Single-Centre Retrospective Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only